 Carolyn Lefkowits
Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genital Neoplasms, Female | 20 | 2023 | 92 | 6.680 |
Why?
| | Cancer Pain | 6 | 2019 | 35 | 2.770 |
Why?
| | Palliative Care | 15 | 2023 | 819 | 2.570 |
Why?
| | Analgesics, Opioid | 7 | 2021 | 1114 | 1.810 |
Why?
| | Pain Management | 5 | 2021 | 395 | 1.520 |
Why?
| | Endometrial Neoplasms | 5 | 2025 | 196 | 1.380 |
Why?
| | Medical Oncology | 8 | 2022 | 316 | 1.370 |
Why?
| | Surgical Oncology | 3 | 2019 | 28 | 1.320 |
Why?
| | Gynecology | 7 | 2020 | 178 | 1.270 |
Why?
| | Hot Flashes | 3 | 2013 | 87 | 1.100 |
Why?
| | Hospice Care | 2 | 2023 | 205 | 0.780 |
Why?
| | Terminal Care | 3 | 2023 | 252 | 0.750 |
Why?
| | Referral and Consultation | 4 | 2017 | 794 | 0.730 |
Why?
| | Opioid-Related Disorders | 5 | 2019 | 562 | 0.650 |
Why?
| | Communication | 3 | 2020 | 948 | 0.570 |
Why?
| | Practice Guidelines as Topic | 2 | 2016 | 1536 | 0.530 |
Why?
| | Perinatal Care | 1 | 2016 | 60 | 0.490 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2019 | 267 | 0.490 |
Why?
| | Attitude of Health Personnel | 3 | 2019 | 1175 | 0.480 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2025 | 1067 | 0.470 |
Why?
| | Neoplasms | 2 | 2021 | 2718 | 0.440 |
Why?
| | Palliative Medicine | 1 | 2014 | 17 | 0.440 |
Why?
| | Obstetrics and Gynecology Department, Hospital | 1 | 2014 | 8 | 0.430 |
Why?
| | Oncology Service, Hospital | 1 | 2014 | 14 | 0.430 |
Why?
| | Female | 33 | 2025 | 75540 | 0.410 |
Why?
| | Ambulatory Care | 2 | 2017 | 584 | 0.390 |
Why?
| | Cyclohexanecarboxylic Acids | 1 | 2013 | 19 | 0.390 |
Why?
| | Amines | 1 | 2013 | 40 | 0.390 |
Why?
| | Cost of Illness | 1 | 2014 | 310 | 0.370 |
Why?
| | Oncologists | 3 | 2022 | 43 | 0.360 |
Why?
| | Complementary Therapies | 1 | 2013 | 90 | 0.360 |
Why?
| | Needs Assessment | 1 | 2014 | 384 | 0.360 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2013 | 195 | 0.340 |
Why?
| | Humans | 36 | 2025 | 140898 | 0.340 |
Why?
| | Quality of Life | 7 | 2025 | 3005 | 0.330 |
Why?
| | Analgesics | 1 | 2013 | 225 | 0.330 |
Why?
| | Radiosurgery | 2 | 2025 | 389 | 0.320 |
Why?
| | Hospice and Palliative Care Nursing | 2 | 2022 | 88 | 0.310 |
Why?
| | Guideline Adherence | 1 | 2014 | 553 | 0.310 |
Why?
| | Education, Medical, Graduate | 1 | 2014 | 523 | 0.310 |
Why?
| | Employment | 2 | 2021 | 179 | 0.300 |
Why?
| | Middle Aged | 18 | 2025 | 34487 | 0.300 |
Why?
| | Health Services Accessibility | 1 | 2016 | 1020 | 0.290 |
Why?
| | Prostatic Neoplasms | 2 | 2013 | 1046 | 0.280 |
Why?
| | Aged | 14 | 2025 | 24666 | 0.280 |
Why?
| | Epidemics | 2 | 2018 | 92 | 0.250 |
Why?
| | Neoplasm Grading | 2 | 2025 | 309 | 0.250 |
Why?
| | Aged, 80 and over | 6 | 2025 | 7899 | 0.240 |
Why?
| | Neoplasm Staging | 3 | 2025 | 1396 | 0.230 |
Why?
| | Ovarian Neoplasms | 2 | 2025 | 580 | 0.230 |
Why?
| | Advance Care Planning | 2 | 2020 | 223 | 0.220 |
Why?
| | Adult | 13 | 2025 | 39134 | 0.210 |
Why?
| | Medical Futility | 1 | 2023 | 28 | 0.200 |
Why?
| | Breast Neoplasms | 2 | 2013 | 2235 | 0.200 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2025 | 133 | 0.200 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2025 | 1786 | 0.190 |
Why?
| | Gynecologic Surgical Procedures | 2 | 2020 | 66 | 0.190 |
Why?
| | Patient Care Team | 2 | 2019 | 664 | 0.190 |
Why?
| | Combined Modality Therapy | 1 | 2025 | 1240 | 0.190 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2013 | 170 | 0.180 |
Why?
| | Indoles | 1 | 2025 | 475 | 0.180 |
Why?
| | Disease Management | 1 | 2025 | 628 | 0.170 |
Why?
| | Brachytherapy | 2 | 2019 | 131 | 0.170 |
Why?
| | Retrospective Studies | 7 | 2022 | 16315 | 0.170 |
Why?
| | Cohort Studies | 4 | 2021 | 5789 | 0.160 |
Why?
| | Ethics, Medical | 1 | 2020 | 83 | 0.160 |
Why?
| | Enoxaparin | 1 | 2020 | 67 | 0.150 |
Why?
| | Infection Control | 1 | 2020 | 165 | 0.150 |
Why?
| | Hospices | 1 | 2020 | 88 | 0.150 |
Why?
| | Carcinoma, Endometrioid | 1 | 2019 | 50 | 0.150 |
Why?
| | Pyridones | 1 | 2020 | 187 | 0.140 |
Why?
| | Carcinosarcoma | 1 | 2018 | 23 | 0.140 |
Why?
| | Postoperative Care | 1 | 2020 | 280 | 0.140 |
Why?
| | Uterine Neoplasms | 1 | 2018 | 92 | 0.140 |
Why?
| | Disease-Free Survival | 1 | 2019 | 713 | 0.140 |
Why?
| | Young Adult | 5 | 2020 | 13646 | 0.130 |
Why?
| | Drug Prescriptions | 1 | 2019 | 263 | 0.130 |
Why?
| | Preoperative Care | 1 | 2019 | 372 | 0.130 |
Why?
| | Drug and Narcotic Control | 1 | 2016 | 26 | 0.130 |
Why?
| | Perinatal Death | 1 | 2016 | 26 | 0.130 |
Why?
| | beta Catenin | 1 | 2019 | 258 | 0.130 |
Why?
| | Survival Analysis | 1 | 2020 | 1320 | 0.130 |
Why?
| | Cancer Care Facilities | 1 | 2017 | 43 | 0.130 |
Why?
| | Truth Disclosure | 1 | 2016 | 46 | 0.120 |
Why?
| | Pyrazoles | 1 | 2020 | 480 | 0.120 |
Why?
| | Nausea | 1 | 2016 | 111 | 0.120 |
Why?
| | Life Expectancy | 1 | 2016 | 71 | 0.120 |
Why?
| | Databases, Factual | 2 | 2019 | 1441 | 0.120 |
Why?
| | Cancer Survivors | 1 | 2020 | 282 | 0.120 |
Why?
| | Venous Thromboembolism | 1 | 2020 | 336 | 0.120 |
Why?
| | Mood Disorders | 1 | 2016 | 139 | 0.120 |
Why?
| | Self Efficacy | 1 | 2019 | 404 | 0.120 |
Why?
| | Anticoagulants | 1 | 2020 | 674 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 371 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 367 | 0.110 |
Why?
| | Program Evaluation | 1 | 2019 | 919 | 0.110 |
Why?
| | Hospitalization | 2 | 2014 | 2261 | 0.110 |
Why?
| | Outpatients | 2 | 2017 | 418 | 0.110 |
Why?
| | Physician-Patient Relations | 1 | 2019 | 580 | 0.110 |
Why?
| | Evidence-Based Medicine | 1 | 2018 | 712 | 0.100 |
Why?
| | Patient Education as Topic | 1 | 2019 | 772 | 0.100 |
Why?
| | Brain Neoplasms | 1 | 2022 | 1275 | 0.100 |
Why?
| | Stellate Ganglion | 1 | 2013 | 6 | 0.100 |
Why?
| | Clonidine | 1 | 2013 | 34 | 0.100 |
Why?
| | Symptom Assessment | 1 | 2014 | 130 | 0.100 |
Why?
| | Societies, Medical | 1 | 2016 | 852 | 0.090 |
Why?
| | Ovariectomy | 1 | 2013 | 158 | 0.090 |
Why?
| | Tamoxifen | 1 | 2013 | 203 | 0.090 |
Why?
| | Hormone Replacement Therapy | 1 | 2013 | 102 | 0.090 |
Why?
| | Anxiety | 1 | 2019 | 1076 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1643 | 0.090 |
Why?
| | Nerve Block | 1 | 2013 | 97 | 0.090 |
Why?
| | Mass Screening | 1 | 2020 | 1300 | 0.090 |
Why?
| | Drug Interactions | 1 | 2013 | 403 | 0.090 |
Why?
| | Continuity of Patient Care | 1 | 2014 | 284 | 0.090 |
Why?
| | Pain | 1 | 2016 | 776 | 0.090 |
Why?
| | Data Collection | 1 | 2014 | 651 | 0.080 |
Why?
| | Fellowships and Scholarships | 1 | 2014 | 323 | 0.080 |
Why?
| | Treatment Outcome | 1 | 2025 | 11125 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1496 | 0.080 |
Why?
| | Depression | 1 | 2019 | 1487 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2018 | 5194 | 0.080 |
Why?
| | Colorado | 1 | 2019 | 4597 | 0.070 |
Why?
| | Logistic Models | 1 | 2014 | 2088 | 0.070 |
Why?
| | Adolescent | 4 | 2020 | 22027 | 0.070 |
Why?
| | Chemoradiotherapy | 2 | 2020 | 232 | 0.070 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2019 | 217 | 0.070 |
Why?
| | Quality Improvement | 1 | 2016 | 1234 | 0.070 |
Why?
| | Postoperative Complications | 1 | 2020 | 2813 | 0.070 |
Why?
| | Curriculum | 1 | 2014 | 1029 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2898 | 0.060 |
Why?
| | United States | 3 | 2020 | 15195 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 5931 | 0.060 |
Why?
| | Maintenance Chemotherapy | 1 | 2025 | 38 | 0.060 |
Why?
| | Infant, Newborn | 1 | 2016 | 6257 | 0.060 |
Why?
| | Risk Factors | 2 | 2019 | 10430 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2021 | 3578 | 0.050 |
Why?
| | Cranial Irradiation | 1 | 2022 | 84 | 0.050 |
Why?
| | Unemployment | 1 | 2020 | 43 | 0.040 |
Why?
| | Health Benefit Plans, Employee | 1 | 2020 | 27 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 1978 | 0.040 |
Why?
| | Resource Allocation | 1 | 2020 | 51 | 0.040 |
Why?
| | Standard of Care | 1 | 2020 | 77 | 0.040 |
Why?
| | DNA Polymerase II | 1 | 2019 | 35 | 0.040 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 33 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2019 | 48 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 97 | 0.040 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 162 | 0.030 |
Why?
| | SEER Program | 1 | 2018 | 219 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 274 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2018 | 380 | 0.030 |
Why?
| | Male | 2 | 2013 | 69893 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 526 | 0.030 |
Why?
| | Critical Care | 1 | 2020 | 650 | 0.030 |
Why?
| | Prognosis | 1 | 2022 | 4060 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1598 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2019 | 1156 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 1243 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 2062 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3484 | 0.020 |
Why?
| | Mutation | 1 | 2019 | 3999 | 0.020 |
Why?
| | Pregnancy | 1 | 2020 | 7035 | 0.020 |
Why?
| | Prospective Studies | 1 | 2017 | 7749 | 0.010 |
Why?
|
|
Lefkowits's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|